Decoy Therapeutics Inc（DCOY）資訊與事件DCOYDecoy Therapeutics Inc

Selling Stockholders Plan to Sell 2.37M Shares of Common Stock

This filing relates to the offer and sale from time to time by the selling stockholders of up to 2.37M shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.

Decoy Therapeutics DCOY-CoV Preclinical Data Supports Once-Weekly Intranasal Administration

Decoy Therapeutics announced preclinical pharmacokinetic, or PK, data supporting once-weekly intranasal administration for its lead program, DCOY-CoV. Results demonstrate that a single intranasal dose maintains therapeutic drug concentrations in both upper respiratory mucosal tissues and deep lung tissue for up to seven days. In preclinical studies, a single intranasal dose showed sustained therapeutic coverage, as drug levels remained above designed antiviral concentrations for seven days post-dose; deep lung & respiratory protection, as high persistence in lung tissue supports protection against lower respiratory tract infections, the primary cause of severe coronavirus-related morbidity. Once-weekly intranasal delivery overcomes compliance barriers inherent in daily oral or inhaled regimens. Apart from COVID-19, there are currently no FDA-approved antiviral treatments or prophylactics for endemic human coronaviruses. DCOY-CoV is expected to enter clinical trials in 2027.

Decoy Therapeutics Explores D-MAVs for Accelerated FDA Approval

Decoy Therapeutics announced a corporate strategy to explore its Designable Multi-Antivirals, or D-MAVs, for additional candidates, including a pan-filovirus program along the FDA Animal Rule pathway for expedited regulatory approval. Based on recent discussions, the company is actively pursuing non-dilutive government grants and public health partnerships to support the preclinical and clinical development of its broad-spectrum biodefense pipeline with monetization potential upon approval via Priority Review Voucher, or PRV, opportunities. By neutralizing the fundamental mechanism of viral entry, Decoy aims to deliver a unified prophylactic solution capable of protecting against Ebola Zaire, Marburg, Sudan, and Bundibugyo viruses simultaneously. The FDA's Animal Rule enables expedited approval for therapeutics targeting lethal pathogens where human efficacy trials are neither ethical nor feasible. This streamlined path significantly reduces clinical timelines and overhead, and positions successful candidates for government procurement and Strategic National Stockpile inclusion.